| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | Chief Financial Officer | Common Stock | 46.8K | $1.33M | $28.43 | Apr 1, 2024 | Direct |
| ROCKET PHARMACEUTICALS, INC. | Chief Financial Officer | Stock Option (Right to Buy) | 69.3K | $870K | $12.55 | Apr 1, 2024 | Direct |
| Mirati Therapeutics, Inc. | Chief Financial Officer | Common Stock | 0 | $59.02 | Jan 23, 2024 | Direct | |
| Mirati Therapeutics, Inc. | Chief Financial Officer | Option to Purchase Common Stock | 0 | Jan 23, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| RCKT | ROCKET PHARMACEUTICALS, INC. | Apr 1, 2024 | 2 | $0 | 4 | Apr 3, 2024 | Chief Financial Officer |
| RCKT | ROCKET PHARMACEUTICALS, INC. | Mar 25, 2024 | 0 | $0 | 3 | Apr 3, 2024 | Chief Financial Officer |
| MRTX | Mirati Therapeutics, Inc. | Jan 23, 2024 | 6 | $0 | 4 | Jan 23, 2024 | Chief Financial Officer |
| MRTX | Mirati Therapeutics, Inc. | Dec 29, 2023 | 1 | $1M | 4 | Jan 3, 2024 | CFO |
| MRTX | Mirati Therapeutics, Inc. | Sep 8, 2023 | 1 | $300K | 4 | Sep 12, 2023 | Interim CFO |
| MRTX | Mirati Therapeutics, Inc. | Sep 8, 2023 | 0 | $0 | 3 | Sep 12, 2023 | Interim CFO |